Group 1 - The core point of the news is that Yinos Biotech experienced a decline of 5.01% in its stock price, reaching 61.00 CNY per share, with a total market capitalization of 8.6 billion CNY [1] - Yinos Biotech, established on May 12, 2010, is located in the China (Shanghai) Pilot Free Trade Zone and specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] - The company's revenue composition indicates a strong focus on non-clinical research, with clinical services contributing only 3.42% and other services at 0.27% [1] Group 2 - Among the top shareholders of Yinos Biotech, a fund under Huatai-PineBridge holds a position, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top shareholders list in Q3 with 1.12 million shares, accounting for 1.24% of the circulating shares [2] - The Huatai-PineBridge Healthcare Mixed Fund has a total scale of 2.486 billion CNY and has achieved a year-to-date return of 8.21%, ranking 2070 out of 8848 in its category [2] - Over the past year, the fund has generated a return of 35.1%, ranking 3677 out of 8093, and since its inception, it has delivered a return of 166.1% [2]
益诺思股价跌5.01%，汇添富基金旗下1只基金位居十大流通股东，持有112.15万股浮亏损失361.13万元